June 12, 2020
Video
Hun Ju Lee, MD, discusses the clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib in a phase 1b/2 study of patients with mantle cell lymphoma or chronic lymphocytic leukemia.